Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04844073 · OUTCOME

t1/2: Terminal Half-Life of TAK-186

A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer · Source last updated 2026-09-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
hours
Interval / dispersion
Full Range
Time frame
Cycle 1: Post-dose on Days 1, 8 and 15; Cycle 2: Post-dose Day 1 (Each cycle is 56 days)

What was measured

t1/2 of TAK-186 was reported. As prespecified in the analysis plan, all participants in this combined cohort received the same target dose level of TAK-186. Therefore, data from these participants were pooled and analyzed as a single cohort.

Analysis population: PK population. "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure \& "number analyzed" signifies participants at specific categories. No participants in Dose Escalation Phase: TAK-186 - Dose A Arm group attended for t1/2. TAK-186 was administered QW and had a LiD regimen including 1-step and 2-step lead-in. Analysis at the lead-in dose time points was not possible due to insufficient data points.

Groups in this outcome

Dose Escalation Phase: TAK-186 - Dose A + Dexamethasone

Participants received TAK-186, Dose A as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose A is the lowest dose.

Dose Escalation Phase: TAK-186 -Dose B + Dexamethasone

Participants received TAK-186, Dose B as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose B is higher than Dose A.

Dose Escalation Phase: TAK-186 -Dose B → Dose C + Dexamethasone

Participants received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose C is higher than Dose B.

Dose Escalation Phase: TAK-186 - Dose B → Dose D + Dexamethasone

Participants received TAK-186, Dose B on Day 1 followed by Dose D on Day 8 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose D is higher than Dose B.

Dose Escalation Phase and Cohort Expansion Phase: TAK-186 - Dose B → Dose C→ Dose E + Dexamethasone

Participants in Dose Escalation Phase and Cohort Expansion Phase received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and Dose E on Day 15 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion and post-infusion. Dose E is higher than Dose C and B.

Dose Escalation Phase: TAK-186 - Dose B→ Dose C→ Dose F + Dexamethasone

Participants received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and Dose F on Day 15 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose F is highest dose and is higher than Dose B and C.

Dose Escalation Phase: TAK-186 - Dose B → Dose C→ Dose D + Dexamethasone

Participants received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and Dose D on Day 15 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone premedication was administered pre-infusion and post-infusion. Dose D is higher than Dose B and C.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Dose Escalation Phase: TAK-186 - Dose A + Dexamethasone0
Dose Escalation Phase: TAK-186 -Dose B + Dexamethasone1
Dose Escalation Phase: TAK-186 -Dose B → Dose C + Dexamethasone4
Dose Escalation Phase: TAK-186 - Dose B → Dose D + Dexamethasone9
Dose Escalation Phase and Cohort Expansion Phase: TAK-186 - Dose B → Dose C→ Dose E + Dexamethasone56
Dose Escalation Phase: TAK-186 - Dose B→ Dose C→ Dose F + Dexamethasone4
Dose Escalation Phase: TAK-186 - Dose B → Dose C→ Dose D + Dexamethasone10

Reported measurements

Cycle 1 Day 1

Analysis denominator · Participants

GroupSource count
Dose Escalation Phase: TAK-186 - Dose A + Dexamethasone0
Dose Escalation Phase: TAK-186 -Dose B + Dexamethasone1
Dose Escalation Phase: TAK-186 -Dose B → Dose C + Dexamethasone0
Dose Escalation Phase: TAK-186 - Dose B → Dose D + Dexamethasone0
Dose Escalation Phase and Cohort Expansion Phase: TAK-186 - Dose B → Dose C→ Dose E + Dexamethasone0
Dose Escalation Phase: TAK-186 - Dose B→ Dose C→ Dose F + Dexamethasone0
Dose Escalation Phase: TAK-186 - Dose B → Dose C→ Dose D + Dexamethasone0
Values in hours · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Dose Escalation Phase: TAK-186 -Dose B + Dexamethasone25.2Not reported25.225.2Not reported
Cycle 1 Day 8

Analysis denominator · Participants

GroupSource count
Dose Escalation Phase: TAK-186 - Dose A + Dexamethasone0
Dose Escalation Phase: TAK-186 -Dose B + Dexamethasone0
Dose Escalation Phase: TAK-186 -Dose B → Dose C + Dexamethasone4
Dose Escalation Phase: TAK-186 - Dose B → Dose D + Dexamethasone9
Dose Escalation Phase and Cohort Expansion Phase: TAK-186 - Dose B → Dose C→ Dose E + Dexamethasone0
Dose Escalation Phase: TAK-186 - Dose B→ Dose C→ Dose F + Dexamethasone0
Dose Escalation Phase: TAK-186 - Dose B → Dose C→ Dose D + Dexamethasone0
Values in hours · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Dose Escalation Phase: TAK-186 -Dose B → Dose C + Dexamethasone15.3Not reported13.417.1Not reported
Dose Escalation Phase: TAK-186 - Dose B → Dose D + Dexamethasone12.7Not reported9.4614.6Not reported
Cycle 1 Day 15

Analysis denominator · Participants

GroupSource count
Dose Escalation Phase: TAK-186 - Dose A + Dexamethasone0
Dose Escalation Phase: TAK-186 -Dose B + Dexamethasone0
Dose Escalation Phase: TAK-186 -Dose B → Dose C + Dexamethasone0
Dose Escalation Phase: TAK-186 - Dose B → Dose D + Dexamethasone0
Dose Escalation Phase and Cohort Expansion Phase: TAK-186 - Dose B → Dose C→ Dose E + Dexamethasone56
Dose Escalation Phase: TAK-186 - Dose B→ Dose C→ Dose F + Dexamethasone4
Dose Escalation Phase: TAK-186 - Dose B → Dose C→ Dose D + Dexamethasone10
Values in hours · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Dose Escalation Phase and Cohort Expansion Phase: TAK-186 - Dose B → Dose C→ Dose E + Dexamethasone14.1Not reported1.7364.2Not reported
Dose Escalation Phase: TAK-186 - Dose B→ Dose C→ Dose F + Dexamethasone10.0Not reported7.2211.6Not reported
Dose Escalation Phase: TAK-186 - Dose B → Dose C→ Dose D + Dexamethasone12.7Not reported9.0418.3Not reported
Cycle 2 Day 1

Analysis denominator · Participants

GroupSource count
Dose Escalation Phase: TAK-186 - Dose A + Dexamethasone0
Dose Escalation Phase: TAK-186 -Dose B + Dexamethasone0
Dose Escalation Phase: TAK-186 -Dose B → Dose C + Dexamethasone0
Dose Escalation Phase: TAK-186 - Dose B → Dose D + Dexamethasone5
Dose Escalation Phase and Cohort Expansion Phase: TAK-186 - Dose B → Dose C→ Dose E + Dexamethasone21
Dose Escalation Phase: TAK-186 - Dose B→ Dose C→ Dose F + Dexamethasone2
Dose Escalation Phase: TAK-186 - Dose B → Dose C→ Dose D + Dexamethasone3
Values in hours · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Dose Escalation Phase: TAK-186 - Dose B → Dose D + Dexamethasone12.4Not reported7.3918.0Not reported
Dose Escalation Phase and Cohort Expansion Phase: TAK-186 - Dose B → Dose C→ Dose E + Dexamethasone28.3Not reported1.4856.8Not reported
Dose Escalation Phase: TAK-186 - Dose B→ Dose C→ Dose F + Dexamethasone46.5Not reported46.546.5Not reported
Dose Escalation Phase: TAK-186 - Dose B → Dose C→ Dose D + Dexamethasone249Not reported30.7468Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG001
        lower Limit
        25.2
        upper Limit
        25.2
        value
        25.2
    denoms
    1. counts
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        1
      3. group Id
        OG002
        value
        0
      4. group Id
        OG003
        value
        0
      5. group Id
        OG004
        value
        0
      6. group Id
        OG005
        value
        0
      7. group Id
        OG006
        value
        0
      units
      Participants
    title
    Cycle 1 Day 1
  2. categories
    1. measurements
      1. group Id
        OG002
        lower Limit
        13.4
        upper Limit
        17.1
        value
        15.3
      2. group Id
        OG003
        lower Limit
        9.46
        upper Limit
        14.6
        value
        12.7
    denoms
    1. counts
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
      3. group Id
        OG002
        value
        4
      4. group Id
        OG003
        value
        9
      5. group Id
        OG004
        value
        0
      6. group Id
        OG005
        value
        0
      7. group Id
        OG006
        value
        0
      units
      Participants
    title
    Cycle 1 Day 8
  3. categories
    1. measurements
      1. group Id
        OG004
        lower Limit
        1.73
        upper Limit
        64.2
        value
        14.1
      2. group Id
        OG005
        lower Limit
        7.22
        upper Limit
        11.6
        value
        10.0
      3. group Id
        OG006
        lower Limit
        9.04
        upper Limit
        18.3
        value
        12.7
    denoms
    1. counts
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
      3. group Id
        OG002
        value
        0
      4. group Id
        OG003
        value
        0
      5. group Id
        OG004
        value
        56
      6. group Id
        OG005
        value
        4
      7. group Id
        OG006
        value
        10
      units
      Participants
    title
    Cycle 1 Day 15
  4. categories
    1. measurements
      1. group Id
        OG003
        lower Limit
        7.39
        upper Limit
        18.0
        value
        12.4
      2. group Id
        OG004
        lower Limit
        1.48
        upper Limit
        56.8
        value
        28.3
      3. group Id
        OG005
        lower Limit
        46.5
        upper Limit
        46.5
        value
        46.5
      4. group Id
        OG006
        lower Limit
        30.7
        upper Limit
        468
        value
        249
    denoms
    1. counts
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
      3. group Id
        OG002
        value
        0
      4. group Id
        OG003
        value
        5
      5. group Id
        OG004
        value
        21
      6. group Id
        OG005
        value
        2
      7. group Id
        OG006
        value
        3
      units
      Participants
    title
    Cycle 2 Day 1
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    2. group Id
      OG001
      value
      1
    3. group Id
      OG002
      value
      4
    4. group Id
      OG003
      value
      9
    5. group Id
      OG004
      value
      56
    6. group Id
      OG005
      value
      4
    7. group Id
      OG006
      value
      10
    units
    Participants
description
t1/2 of TAK-186 was reported. As prespecified in the analysis plan, all participants in this combined cohort received the same target dose level of TAK-186. Therefore, data from these participants were pooled and analyzed as a single cohort.
dispersion Type
Full Range
groups
  1. description
    Participants received TAK-186, Dose A as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose A is the lowest dose.
    id
    OG000
    title
    Dose Escalation Phase: TAK-186 - Dose A + Dexamethasone
  2. description
    Participants received TAK-186, Dose B as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose B is higher than Dose A.
    id
    OG001
    title
    Dose Escalation Phase: TAK-186 -Dose B + Dexamethasone
  3. description
    Participants received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose C is higher than Dose B.
    id
    OG002
    title
    Dose Escalation Phase: TAK-186 -Dose B → Dose C + Dexamethasone
  4. description
    Participants received TAK-186, Dose B on Day 1 followed by Dose D on Day 8 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose D is higher than Dose B.
    id
    OG003
    title
    Dose Escalation Phase: TAK-186 - Dose B → Dose D + Dexamethasone
  5. description
    Participants in Dose Escalation Phase and Cohort Expansion Phase received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and Dose E on Day 15 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion and post-infusion. Dose E is higher than Dose C and B.
    id
    OG004
    title
    Dose Escalation Phase and Cohort Expansion Phase: TAK-186 - Dose B → Dose C→ Dose E + Dexamethasone
  6. description
    Participants received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and Dose F on Day 15 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose F is highest dose and is higher than Dose B and C.
    id
    OG005
    title
    Dose Escalation Phase: TAK-186 - Dose B→ Dose C→ Dose F + Dexamethasone
  7. description
    Participants received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and Dose D on Day 15 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone premedication was administered pre-infusion and post-infusion. Dose D is higher than Dose B and C.
    id
    OG006
    title
    Dose Escalation Phase: TAK-186 - Dose B → Dose C→ Dose D + Dexamethasone
param Type
MEDIAN
population Description
PK population. "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure \& "number analyzed" signifies participants at specific categories. No participants in Dose Escalation Phase: TAK-186 - Dose A Arm group attended for t1/2. TAK-186 was administered QW and had a LiD regimen including 1-step and 2-step lead-in. Analysis at the lead-in dose time points was not possible due to insufficient data points.
reporting Status
POSTED
time Frame
Cycle 1: Post-dose on Days 1, 8 and 15; Cycle 2: Post-dose Day 1 (Each cycle is 56 days)
title
t1/2: Terminal Half-Life of TAK-186
type
SECONDARY
unit Of Measure
hours

Download exact source JSON → · Snapshot ctgov-results-d643ffaf417bcef6d45eb5e0

Preserved source evidence · Not medical advice